Objective To establish a tumor animal model with clear cell renal cancer cells from patients, and to detect the sensitivity of ccRCC PDCs to molecular targeted drugs, so as to provide theoretical and experimental basis for clinical diagnosis and treatment.
Methods The tumor model was established by subcutaneous inoculation of ccRCC PDCs in nude mice. The molecular targeted drugs sunitinib, sorafenib, lovatinib, regofinib, apatinib and anotinib were orally administered by gavage to determine the inhibitory effect of the drugs on the subcutaneous tumorigenesis of ccRCC PDCs in nude mice. Collect cell and tumor tissue samples, and use quantitative PCR technology to detect molecular targeted drug action targets (tyrosine protein kinase of VEGFR and other receptors and protein kinase of ERK, AKT and other MAPK signal pathways), to determine whether the genetic background of ccRCC PDCs remains stable during the experiment.
Results Five strains of ccRCC PDCs were successfully obtained and the subcutaneous tumor model of renal carcinoma was obtained by inoculating the above ccRCC PDCs into nude mice; In the process of culturing PDCs cells in vitro, the expression of molecular targeted drug targets decreased or lost, while the expression of molecular targeted drug targets in tumor tissue was relatively stable when PDCs cells were expanded by tumorigenesis in nude mice; The inhibition effect of molecular targeted drugs on the subcutaneous tumorigenesis of ccRCC PDCs in nude mice has individual differences with clear patient origin. Among the selected molecular targeted drugs, Lenvatinib has stronger anti-tumor activity than other molecular targeted drugs.
Conclusion This study successfully established an animal model of renal cell carcinoma using clear cell renal cell carcinoma cell lines from patients and tested the sensitivity of renal cell carcinoma cells to molecular targeted drugs, which can provide theoretical and experimental basis for relevant clinical diagnosis and treatment.